Adrian Haigh
Chief Operating Officer chez FENNEC PHARMACEUTICALS INC.
Fortune : - $ au 29/02/2024
Profil
Adrian James Haigh holds the position of Chief Operating Officer at Fennec Pharmaceuticals, Inc. He is also on the board of PTC Therapeutics Ltd.
In his past career he held the position of General Manager-Portugal & Scandinavia at Amgen, Inc., Senior Vice President & GM-EMEA Region at PTC Therapeutics, Inc., Principal at GSK Plc, COO & Senior Vice President-Commercial Operations at Gentium GmbH, Principal at Schering-Plough Corp., Senior Vice President-Commercial Operations at Gentium Srl, Principal at N.V.
Organon, Principal at Novo Nordisk, Inc., Regional Vice President-Commercial Operations at Biogen Canada, Inc., Regional Vice President-Commercial Operations at Biogen International GmbH and Executive VP-Global Marketing & Corporate Planning at EUSA Pharma, Inc.
He received an undergraduate degree from the University of Huddersfield.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
07/08/2023 | 0 ( -.--% ) | - $ | 29/02/2024 |
Postes actifs de Adrian Haigh
Sociétés | Poste | Début |
---|---|---|
FENNEC PHARMACEUTICALS INC. | Chief Operating Officer | 03/08/2023 |
PTC Therapeutics Ltd.
PTC Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Founded in 2012, PTC Therapeutics Ltd. is a British pharmaceutical company that develops pharmaceutical products. Part of PTC Therapeutics, Inc., the private company is based in London, UK. | Director/Board Member | 09/11/2014 |
Anciens postes connus de Adrian Haigh
Sociétés | Poste | Fin |
---|---|---|
PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 31/12/2022 |
ARCH BIOPARTNERS INC. | Director/Board Member | 10/06/2021 |
AMGEN INC. | Corporate Officer/Principal | 01/01/2007 |
Biogen Canada, Inc. | Corporate Officer/Principal | - |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Sales & Marketing | - |
Formation de Adrian Haigh
University of Huddersfield | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 5 |
---|---|
AMGEN INC. | Health Technology |
FENNEC PHARMACEUTICALS INC. | Health Technology |
PTC THERAPEUTICS, INC. | Health Technology |
GSK PLC | Health Technology |
ARCH BIOPARTNERS INC. | Health Technology |
Entreprise privées | 9 |
---|---|
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Gentium Srl
Gentium Srl Pharmaceuticals: MajorHealth Technology Gentium SRL manufactures and develops biopharmaceutical products. It offers discovery, research, development and manufacture of drugs for the treatment and prevention of a variety of vascular diseases and conditions related to cancer and cancer treatments. The company was founded by Laura Iris Ferro and is headquartered in Villa Guardia, Italy. | Health Technology |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Health Technology |
Organon NV
Organon NV Pharmaceuticals: MajorHealth Technology N.V. Organon engages in the development, manufacture, and sale of prescription medicines. It offers products for cardiovascular diseases, fertility, gynecology, anesthesia, respiratory, consumer health care, neuroscience as well as immunology, animal health, and oncology. Its products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. The company was founded in 1923 and is headquartered in Oss, the Netherlands. | Health Technology |
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
Biogen Canada, Inc. | |
Biogen International GmbH
Biogen International GmbH Pharmaceuticals: MajorHealth Technology Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland. | Health Technology |
Gentium GmbH | |
PTC Therapeutics Ltd.
PTC Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Founded in 2012, PTC Therapeutics Ltd. is a British pharmaceutical company that develops pharmaceutical products. Part of PTC Therapeutics, Inc., the private company is based in London, UK. | Health Technology |